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CONSENSuS
Statement

A framework for advancing our
understanding of cancer-associated
fibroblasts
Erik Sahai 1*, Igor Astsaturov 2, Edna Cukierman3, David G. DeNardo 4,
Mikala Egeblad5, Ronald M. Evans6,7, Douglas Fearon5,8, Florian R. Greten 9,10,
Sunil R. Hingorani11, Tony Hunter12, Richard O. Hynes13, Rakesh K. Jain 14,
Tobias Janowitz5,15, Claus Jorgensen16, Alec C. Kimmelman17, Mikhail G. Kolonin18,
Robert G. Maki5,19,32, R. Scott Powers20, Ellen Puré21, Daniel C. Ramirez22,
Ruth Scherz-Shouval23, Mara H. Sherman24, Sheila Stewart 25, Thea D. Tlsty26,27,
David A. Tuveson5, Fiona M. Watt 28, Valerie Weaver29, Ashani T. Weeraratna30
and Zena Werb 31

Abstract | Cancer-associated fibroblasts (CAFs) are a key component of the tumour
microenvironment with diverse functions, including matrix deposition and remodelling,
extensive reciprocal signalling interactions with cancer cells and crosstalk with infiltrating
leukocytes. As such, they are a potential target for optimizing therapeutic strategies against
cancer. However, many challenges are present in ongoing attempts to modulate CAFs for
therapeutic benefit. These include limitations in our understanding of the origin of CAFs and
heterogeneity in CAF function, with it being desirable to retain some antitumorigenic functions.
On the basis of a meeting of experts in the field of CAF biology, we summarize in this Consensus
Statement our current knowledge and present a framework for advancing our understanding
of this critical cell type within the tumour microenvironment.
Extracellular matrix
(ECM).The structural network
of secreted proteins and
glycosaminoglycans that
provides structure to tissue.

Angiogenesis
The formation of new blood
vessels.

Mesenchyme
A type of tissue composed
of loosely associated cells
surrounded by extracellular
matrix.

Mesoderm
One of three fundamental
layers of tissue formed early
in development and the
predominant source of
fibroblastic lineages.
*e-mail: erik.sahai@
crick.ac.uk
https://doi.org/10.1038/
s41568-019-0238-1

Cancer arises from mutations accruing within cancer
cells, but both disease progression and responses to
therapy are strongly modulated by non-mutant cells
within the tumour microenvironment. The past few
years have witnessed a great expansion in research
into cancer-associated fibroblasts (CAFs). These cells
modulate cancer metastasis through synthesis and
remodelling of the extracellular matrix (ECM) and production of growth factors, and influence angiogenesis,
tumour mechanics, drug access and therapy responses.
More recently, there has been a growing appreciation
of the ability of CAFs to modulate the immune system.
Targeting CAFs, by altering their numbers, subtype or
functionality, is being explored as an avenue to improve
cancer therapies. However, research in this area faces
numerous challenges — not least because CAFs can have
both protumorigenic and antitumorigenic effects. This
Consensus Statement follows a recent Banbury Center
meeting at Cold Spring Harbor Laboratory (New York,
USA) held in March 2019, which focused on CAF bio
logy and therapeutic opportunities and included an
open discussion to identify the challenges facing CAF
research and suggest ways forward (Box 1). On the basis
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of this, we, as an international group of cancer researchers and clinician scientists, herein present the current
state of CAF research, summarize the challenges ahead
and present both methodological advice and conceptual suggestions to provide the necessary framework to
advance the field.

What is a fibroblast?
The definition of a fibroblast is surprisingly tricky1,2. The
embryonic origin of most fibroblasts is from the primitive mesenchyme that develops out of the mesoderm following gastrulation3, with a smaller subset of fibroblasts
also derived from the neural crest, which is part of the
ectoderm4. This embryonic origin is shared by other
mesenchymal lineages, including adipocytes, chondrocytes and osteoblasts. The difficulty in defining fibroblasts
results largely from the lack of unique markers that are
not expressed in any other cell types. The result is that in
practical terms, fibroblasts are often defined by a combination of their morphology, tissue position and lack of
lineage markers for epithelial cells, endothelial cells and
leukocytes. Vimentin and platelet-derived growth factor
receptor-α (PDGFRα) are sometimes used but typically
www.nature.com/nrc
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Neural crest
Migratory mesenchymal cells
derived from the neural tube
and originally the ectoderm.

Adipocytes
Mesenchymal cells specialized
for the storage of fat.

Pericytes
Mesenchymal cells that are
located adjacent to smaller
blood vessels and that support
their function.

alongside other criteria such as cell shape and location.
Markers for fibroblast subtypes also exist, including
α-smooth muscle actin (αSMA; also known as ACTA2)
and fibroblast activation protein (FAP)5,6, with the subset of fibroblasts expressing the latter playing roles in
bone and fat homeostasis. Recent work is beginning to
trace the lineage of fibroblasts from the earliest stage of
mesenchyme specification through to the adult. This has
already highlighted distinct subsets of dermal fibroblasts
and is starting to provide more precise combinations of
markers with which to define fibroblasts7,8. However, the
links between lineage commitment in early development
and the fibroblast subsets found in the adult remain, for
the most part, to be determined.
In normal development and physiology, fibroblasts
are the major producers of connective tissue ECM, with
emerging data indicating that this function is modified
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with age9,10. They also play a key role in tissue repair and
become activated following tissue damage11. During
wound healing they can produce transforming growth
factor-β (TGFβ) and acquire a highly contractile phenotype associated with the expression of αSMA12. In this
state, fibroblasts are termed ‘myofibroblasts’. Both in
normal homeostasis and following injury they participate in crosstalk with adjacent epithelia, with numerous
studies documenting an ability to influence local epithelial stem cell behaviour13,14. They can also promote
angiogenesis via the production of vascular endothelial
growth factor A (VEGFA)15 and coordinate the function
of the immune system via the production of chemokines
and cytokines, although it should be noted that there
is heterogeneity in the cytokines produced by different
fibroblasts16–20. Fibroblasts also play a structural role
within the immune system; fibroblastic reticular cells
(FRCs) within lymph nodes generate ECM conduits for
the transit of potential antigens and serve as migration
‘highways’ for leukocytes21. This allows effective immune
surveillance. In addition, they promote immune tolerance by the expression and presentation of normally
tissue-restricted antigens22. Emerging work is revealing
complex crosstalk between fibroblastic cells and epithelial cells in exocrine organs. For example, stellate cells are
a distinctive type of fibroblast found in the liver and pancreas that store lipid droplets and particular derivatives
of retinoic acid. The balance between quiescence and
activation of stellate cells is regulated by the vitamin D
receptor, deletion of which leads to spontaneous liver
and pancreas fibrosis23, with further work indicating
that stellate cells play a broader role in metabolic homeo
stasis24–26. Thus, fibroblasts are not simply producers of
ECM but play key roles in communicating with many
other cell types during both normal tissue homeostasis
and repair.

What is a CAF?
To first consider how CAFs are generated, it is important
to try to define CAFs. Many of the same issues arising
for normal fibroblasts also apply to CAFs. When analysing tissue biopsy samples, the simplest view is that cells
negative for epithelial, endothelial and leukocyte markers
with an elongated morphology and lacking the mutations
found within cancer cells might be considered CAFs. The
latter point is important because it excludes cancer cells
that have undergone a profound epithelial to mesenchymal transition (EMT), although such cells are likely to
be of considerable importance and warrant studying in
their own right. In practice, lineage exclusion is typically
combined with positivity for a mesenchymal marker,
often vimentin; however, this may not be sufficient to
exclude other mesenchymal lineages such as pericytes
or adipocytes. Early experimental studies indicated
that such cells cultured from tumours have distinctive
properties compared with normal fibroblasts27. In practice, any mesenchymal cell cultured from a tumour that
complies with the criteria described above is considered
a CAF. Nevertheless, as discussed in the section entitled
‘Challenges and recommendations’, how durable CAF
subsets and phenotypes remain once fibroblasts are
isolated and cultured warrants further investigation.
volume 20 | March 2020 | 175
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Box 1 | Generation of this Consensus Statement
This Banbury Center meeting convened experts to discuss
our current understanding of cancer-associated fibroblast
(CAF) biology, with an emphasis on optimizing new
approaches being developed to probe the fundamental
properties of CAFs, and medical applications of CAF
targeting. Following the introductory remarks, the idea of
summarizing the outputs from the meeting in a Consensus
Statement was proposed and unanimously approved.
An open discussion with all meeting participants was
held on the final day of the meeting to collate ideas about
what the Consensus Statement should contain and
how it should be structured. A draft statement was then
circulated to all authors for feedback and refinement,
leading to agreement with the views expressed in this
Consensus Statement.

What is the origin of CAFs?
The lack of precision around fibroblast-specific markers
poses a challenge when one is considering the origin of
CAFs. When the markers of both normal tissue-resident
fibroblasts and CAFs are ill-defined, it becomes very
hard to propose hypotheses regarding the precise cell of
origin of CAFs. To partially circumvent this problem,
many studies have documented the changes in the fibroblastic component of carcinomas as they progress from
hyperplasia, through adenoma or in situ lesion, to frank
carcinoma in patients28. These studies using human
tissue observe progressive changes in the fibroblastic
stroma. In many cases, the initial apparent expansion
of fibroblasts precedes the conversion to malignancy,
and fibroblasts are often observed circumscribing
early or premalignant lesions29,30. The gradual nature
of the transitions observed has given rise to the view
that the majority of stromal fibroblasts initially originate from local fibroblasts that experience some form of
tissue dysfunction31,32. The expansion of stromal fibroblast number could result from proliferation, which has
been experimentally observed in tumours, albeit with
low frequency33. This process has been termed ‘stroma
genesis’, with the implication that it proceeds alongside and is coupled to tumorigenesis34. Furthermore,
experimental studies and observations of early lesions
encircled by fibroblasts support the idea that the initial fibroblast response can be tumour suppressive35,36,
with subsequent events in stromagenesis generating
protumorigenic fibroblasts. It is currently difficult to
explore this hypothesis in human tissue biopsy samples because longitudinal sampling of the same lesion
through disease progression is rarely possible and, even
when it is, the conversion between cell states cannot be
directly tracked.
To shed more light on the origin of CAFs, many
researchers have turned to mouse models in which cells
can be irreversibly labelled using transgenic techniques
and well-characterized models of disease progression are
available. These typically use tissue-restricted expression of the Cre recombinase in mice that also contain
a reporter gene that becomes irreversibly active in cells
that express Cre. Importantly, the active reporter will
be inherited by all daughter cells and will continue to be
expressed even if the Cre recombinase is not37. However,
176 | March 2020 | volume 20

the lack of fibroblast-restricted markers causes problems
when one is selecting a promoter to drive the expression
of the Cre recombinase. This is exemplified by the divergent phenotypes observed in a colitis model of stromal
knockout of Ikkb (inhibitor of nuclear factor-κB (NF-κB)
kinase subunit-β) depending on whether a collagen
type I α2 chain (Col1a2) or collagen type V α1 chain
(Col5a1) Cre driver was used38,39. The most widely used
fibroblast drivers and their caveats are detailed in the
section entitled ‘Challenges and recommendations’. This
approach can also be used to explore hypotheses including the conversion of adipocytes, pericytes, endothelial
cells and bone marrow-derived mesenchymal stem cells
(MSCs) into CAFs. The injection of bone marrow-
derived MSCs into tumour-bearing mice has demonstrated that they can become CAFs40, with more recent
studies supporting the MSC origin of PDGFRα– CAFs41.
Adipocyte conversion into CAFs has been reported by
several groups, although it does not appear to be a universally applicable phenomenon across different tumour
types42–45. The reduction or absence of adipocytes in
pathological tissue could also result from activated fibroblasts interfering with adipocyte differentiation46. In situ
ations where adipocytes remain, they can engage in
crosstalk with cancer cells and provide metabolic support independently of conversion into CAFs47. Evidence
for pericyte conversion into CAFs is relatively sparse48,
with tumorigenesis studies that targeted pericytes speci
fically not revealing large-scale differences in the tumour
microenvironment.
Ultimately, lineage tracing studies in mice remain
hampered by the lack of highly specific Cre drivers for
normal fibroblasts, difficulties of combining lineage
tracing with genetically engineered models of mouse
tumours that are also driven by Cre recombinase, the
suboptimal nature of cell line-based tumour models
and the lack of incentives to report negative data in such
studies. Currently, it is also unclear whether individual
CAF populations are preserved across tissues and species. While single-cell sequencing indicates common
traits are preserved49–51, it will become increasingly
pressing to define common and specific effects of CAFs.
Techniques that provide spatial resolution, such as highly
multiplexed antibody-based staining and multiplexed
nucleic acid in situ hybridization, will also have a role
to play in determining whether CAF subtype is strongly
influenced by spatial location within the tumour.
Together, these factors mean that definitive conclusions
on the origin of CAFs are hard to reach. The consensus
is that most CAFs likely result from the activation of
local tissue-resident fibroblasts but that there are clear
examples of alternative origins.

How are CAFs generated?
The studies described in the previous section aimed to
document which cells give rise to CAFs but do not provide
a mechanism for their conversion. Given the prominent
role fibroblasts play in coordinating the wound repair
response in skin, it is plausible that key CAF traits correspond to the normal physiological role fibroblasts play.
Well-e stablished activating signals for fibroblasts
include TGFβ family ligands and the lipid mediator
www.nature.com/nrc
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lysophosphatidic acid52–54, which promote the activity
of the SMAD transcription factors and serum response
factor (SRF), respectively, and converge to drive expression of the activated fibroblast marker αSMA as well
as increase the activity of the contractile cytoskeleton6
(Fig. 1). Contact between cancer cells and fibroblasts can
promote the CAF phenotype in breast cancer through
Notch signalling55; however, this mechanism is unlikely
to be universal as loss of Notch signalling can promote
CAF phenotypes in squamous cell carcinoma56. Various
inflammatory modulators can promote CAF activation,
with interleukin-1 (IL-1) acting through NF-κB and
IL-6 acting primarily on signal transducer and activator of transcription (STAT) transcription factors57,58.
Crosstalk and positive feedback involving Janus kinase
(JAK)–STAT signalling, the contractile cytoskeleton
and alterations in histone acetylation further promote
CAF activation59,60. Physical changes in the ECM are
also capable of activating CAFs53,61–64. In vitro studies have shown that fibroblast stretching, which may
result from the hyperproliferation of transformed epithelial cells, can activate SRF-driven transcription and
Yes-associated protein 1 (YAP1)–TEAD-driven trans
cription53,54,65,66. These transcription factors cooperate to
drive the expression of a wide-range of genes associated
with CAFs, including the genes encoding connective
tissue growth factor (CTGF; also known as CCN2) and
cysteine-rich angiogenic inducer 61 (CYR61; also known as
CCN1)54. Furthermore, matricellular molecules, such
as CTGF and CYR61, and the contractile cytoskeleton
cooperate to increase tissue stiffness, which further
drives SRF-dependent and YAP1-dependent transcriptional programmes, locking CAFs into a self-sustaining
positive-feedback loop53. Physiological stress is also
another factor contributing to stromagenesis. Heat
shock factor 1 (HSF1), which responds in part to protein
misfolding, is required for the generation of CAFs67,68.
Physiological and genomic stresses can also trigger
changes in fibroblasts. Double-stranded DNA breaks can
promote the production of IL-6 and the TGFβ family
ligand activin A69,70. In some cases, these triggers cause
DNA damage
(chemotherapy
and radiotherapy)

TGFβ

Physiological stress
(ROS and disrupted
metabolism)

Extracellular matrix
(stiffness and composition)

Inflammatory signals
(IL-1, IL-6 and TNF)

Contact signals
(Notch and Eph–ephrins)

RTK ligands (PDGF and FGF)
Normal fibroblast
CAF
activation
CAF

Fig. 1 | Diverse mechanisms of cancer-associated fibroblast activation. This schematic
highlights the multiple mechanisms that can contribute to cancer-associated fibroblast
(CAF) activation. FGF, fibroblast growth factor; PDGF, platelet-derived growth factor;
ROS, reactive oxygen species; RTK, receptor tyrosine kinase; TGFβ, transforming growth
factor-β; TNF, tumour necrosis factor.
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fibroblasts to enter a non-proliferative state termed
‘senescence’71, which is distinct from the phenotype of
an aged fibroblast. There is clear overlap between the
secretome of senescent fibroblasts and CAFs, with high
levels of IL-6 production being common to both, and
senescent fibroblasts have been found in the micro
environment of some tumours72. The non-proliferative
nature of senescent cells makes it unlikely that they are
a major contributor to the abundant stromal fibroblasts
observed in desmoplastic tumours73. Nonetheless, it
remains possible that CAFs and senescent fibroblasts
share some transcriptional regulatory mechanisms74,75.
Furthermore, even if senescent fibroblasts are a minor
component of the tumour microenvironment, experimental analysis suggests that their elimination can have
substantial consequences for disease relapse71.
In addition to considering tumour cells as the direct
source of cues that generate CAFs, signals from other
cells within the tumour microenvironment may also
instruct CAF function; for example, granulin produced
by macrophages promotes the activation of a fibrotic
environment in liver metastases76,77. Such mechanisms
that do not directly depend on the presence of cancer
may contribute to the protumorigenic environments
found in inflammatory conditions that are linked to
increased cancer risk. In addition, cancer therapies,
including conventional chemotherapies, radiotherapy
and targeted agents, can promote the generation of
CAFs and modulate their functionality. These changes
can aid the development of therapy resistance78–80 and
contribute to undesirable side effects80. Being able to
mitigate these events is another potential appeal of
CAF-directed therapies.

The expanding range of CAF functions
The functions of CAFs have been determined using
a variety of strategies, ranging from reductionist cell
culture experiments and mouse models to correlative
associations in large patient cohorts. These approaches
have revealed a diverse array of functions (Fig. 2). The
relative ease of culturing CAFs and matched normal
fibroblasts from patient material has greatly facilitated mechanistic delineation of CAF functions. CAFs
are perhaps the most effective cell within the tumour
microenvironment at depositing and remodelling
the ECM. This depends on RHO and RAB GTPase-
mediated control of integrin-mediated adhesions and
the actomyosin cytoskeleton81–83 and is linked to downregulation of the transmembrane receptor CD36 (also
known as platelet glycoprotein 4)84. CAFs also produce
matrix-crosslinking enzymes and, together with force-
mediated ECM remodelling (reviewed in detail85,86),
these contribute to the increased stiffness of tumour
tissue87–89. Although chemical crosslinks are not readily
reversed, the production of matrix proteases allows the
tumour matrix to be remodelled, and this can lead to
the generation of permissive tracks that allow cancer
cell invasion81. Contact-mediated Eph–ephrin signalling
further influences cancer cell migration90. In addition to
promoting local invasion, CAFs are able to boost meta
stasis in experimental models, and this correlated with
their ability to remodel the ECM91–93. Once cancer cells
volume 20 | March 2020 | 177
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Cancer invasion

Macrophage
and endothelial
crosstalk

Soluble secreted
factors
• VEGF
• Exosomes
• HGF and GAS6
production

Tumour growth

Matrix remodelling
• Matrix crosslinking
• Proteolysis
• Force-mediated
matrix remodelling
• Matrix production

Immune crosstalk
• TGFβ activation
• IL-6 production
• CXCL12
production
• CCL2 production

CAF

Interference with
T cell function

Metabolic effects
• Lactate shuttling
• Alanine and aspartate shuttling
• Amino acid depletion

Fig. 2 | Summary of cancer-associated fibroblast functions and the mechanisms by which they are achieved.
Dark blue text boxes indicate the biological functions being regulated, with light blue, green, purple and grey text boxes
indicating the processes and mechanisms leading to the control of function. Lines connect mechanisms to functions.
Both matrix remodelling and the production of soluble factors contribute to increased tumour cell invasion. Soluble
factors also contribute to changes in tumour growth and the immune microenvironment, which is also affected by the
altered metabolic state of the tumour. CAF, cancer-associated fibroblast; CCL2, CC-chemokine ligand 2; CXCL12,
CXC-chemokine ligand 12; IL-6, interleukin-6; GAS6, growth arrest-specific protein 6; HGF, hepatocyte growth factor;
TGFβ, transforming growth factor-β; VEGF, vascular endothelial growth factor.

Focal adhesion kinase
(FAK). A kinase that links
integrin extracellular matrix
receptors to intracellular
changes in cell signalling.

Tumour necrosis factor
(TNF). A cytokine that is
produced under conditions
of tissue stress and promotes
inflammation.

Autophagy
A process of cellular ‘self-
eating’ that serves to remove
damaged organelles and
provide metabolic resources.

have disseminated, the de novo activation of fibroblasts
at secondary sites favours the establishment of macro
metastases via multiple mechanisms, including the
production of matrix components such as tenascin and
periostin that provide supporting signals to the cancer
cells94,95. These molecules boost WNT signalling94, which
may link to the role of some fibroblasts in normal physio
logy in regulating stem cell niches that are rich in WNT
ligands96,97. More recently, changes in ECM organization
have been shown to influence the migration of infiltrating leukocytes, which has implications for the immune
surveillance of tumours98.
The alterations in matrix production and tumour
mechanics that result in a large part from the action of
CAFs have complex consequences for tumours. Increased
tissue stiffness triggers prosurvival and proproliferation
signalling in cancer cells99. Increased mechanical stress
can collapse blood vessels, leading to hypoxia, thereby
promoting more aggressive cancer phenotypes, and
reducing drug delivery89,100–105. Altered tissue mechanics are also likely to play a role in cancer development
and premalignant disease; this is evidenced by the links
between mammographic density and breast cancer incidence84. Targeting the interplay between CAFs and the
mechanical properties of tumours for patient benefit is
currently being explored (see Table 1).
CAFs are also a substantial source of growth factors,
cytokines and exosomes that can promote tumour
growth and modulate therapy responses27,106–108. The
production of TGFβ, leukaemia inhibitory factor (LIF),
growth arrest-specific protein 6 (GAS6), fibroblast
growth factor 5 (FGF5), growth differentiation factor 15
(GDF15) and hepatocyte growth factor (HGF) promotes invasive and proliferative behaviour in cancer
cells52,109–112. In addition, HGF has been implicated in
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mediating resistance to BRAF-targeted therapies by providing an alternative BRAF-independent mechanism for
ERK–MAPK activation113.
The secretome of CAFs also influences other components of the tumour microenvironment. VEGF
expression by stromal cells can drive angiogenesis15,114.
Numerous cytokines and chemokines are produced by
CAFs, and these act on a range of leukocytes, including
CD8+ T cells, regulatory T (Treg) cells and macrophages,
with both immunosuppressive and immunopromoting consequences115. However, the consensus is that
the predominant effect of CAFs is immunosuppressive with IL-6, CXC-chemokine ligand 9 (CXCL9) and
TGFβ having well-established roles in reducing T cell
responses116. More recently, antigen cross presentation
by CAFs has been observed117, and this may lead to CD4+
T cell activation and suppression of CD8+ T cells118.
Clinical analysis further supports an inverse association between CAFs and CD8+ T cells119. IL-6 may also
promote immunosuppression via systemic effects on
metabolism120. Interference with the action of CXCL12
produced by CAFs promotes T cell-mediated tumour
control16,121,122, and targeting focal adhesion kinase (FAK)
in cancer cells concomitantly reduces stromal fibroblast activation and the development of an immuno
suppressive environment123. However, the situation with
tumour necrosis factor (TNF) produced by CAFs is more
nuanced; the tumour-promoting immunosuppressive
activity of FAP+ fibroblasts is associated with suppression
of TNF signalling, yet TNF is also able to drive fibroblast
activation in certain contexts16,124,125.
The exchange of metabolites and amino acids
between cancer cells and CAFs is an additional avenue by which stromal fibroblasts interact with tumour
cells126–129. Autophagy in stromal fibroblasts can generate
www.nature.com/nrc
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Table 1 | Current cancer-associated fibroblast clinical trial activity
Target

Name

Drug or biologic

Mechanism

Current status

Interference with CAF activation
FGFR

JNJ-42756493

Small-molecule inhibitor

Prevents CAF activation

Phase I and phase II trials
under way170

Hedgehog

IPI-926 (saridegib)
and vismodegib

Small-molecule inhibitor

Reduces CAF activation

Clinical trials ongoing; some
reported lack of efficacy169,171

Interference with CAF activation and CAF action
TGFβ

Various, including
galunisertib

Both blocking Abs and
small-molecule receptor
inhibitors

Prevents CAF activation and
immunosuppression

Phase I, phase II and phase III
trials under way172,173

Angiotensin receptor

Losartan

Small-molecule inhibitor

Reduces collagen and hyaluronan
levels

Phase II trial completed;
randomized trial ongoing174,175

Interference with CAF action
CXCR4

AMD3100

Small-molecule inhibitor

Prevents signalling from CAFs
to immune cells

Clinical trials ongoing176

ROCK

AT13148

Small-molecule inhibitor

Reduces contractility

Phase I trial completed177

FAK

Defactinib (VS-6063,
PF-04554878)

Small-molecule inhibitor

Reduces signalling downstream
of integrins

Clinical trials ongoing178

LOXL2

Simtuzumab (GS 6624)

Blocking Ab

Anticrosslinking

Preclinical and fibrosis trials179

CTGF

FG-3019

Blocking Ab

Blocks binding to receptors,
including integrins

Early-phase clinical trials
ongoing

Hyaluronic acid

PEGPH20 (PVHA)

Pegylated enzyme

ECM degradation to increase the
access and efficacy of cytotoxic
therapies and immunotherapies

Phase III trial complete,
awaiting final analysis180,181

FAP-expressing cells

Various, including
Blocking Abs (sibrotuzumab I Blocks FAP+ CAF function,
PT630 and RO6874281 (ref.182), molecular
promoting T cell function
radiotherapy, inhibitors
(PT630) or an Ab–IL-2 fusion
(RO6874281)

Phase I and phase II trials
under way183

CAF normalization
Vitamin A metabolism ATRA

Vitamin A metabolite

‘Normalizes’ stellate cells

Clinical trials ongoing184,185

Vitamin D receptor

Small-molecule agonist

‘Normalizes’ stellate cells

Clinical trial started186

Paricalcitol

Ab, antibody; ATRA, all-trans retinoic acid; CAF, cancer-associated fibroblast; CTGF, connective tissue growth factor; CXCR4, CXC-chemokine receptor 4;
ECM, extracellular matrix; FAK, focal adhesion kinase; FAP, fibroblast activation protein; FGFR, fibroblast growth factor receptor; IL-2, interleukin-2;
LOXL2, lysyl oxidase-like 2; ROCK, RHO kinase; TGFβ, transforming growth factor-β.

alanine, which is subsequently used by pancreatic ductal
adenocarcinoma (PDAC) cells to fuel the tricarbox
ylic acid (TCA) cycle126,130,131. Furthermore, metabolic
dysregulation of CAFs may also be coupled to altered
immunoregulation, possibly through IL-6 production
or depletion of immunomodulating amino acids128,132.

CAF heterogeneity and plasticity
The large array of functions attributed to CAFs in a
range of model systems poses the question of whether
a single type of CAF simultaneously performs all these
functions or whether there is subspecialization of CAFs
and possibly switching between distinct functional
states. Overwhelming evidence now points to a degree
of specialization among CAFs, which may reflect the
increasingly appreciated specialization of normal
fibroblasts19,50. This is informed by the increasing array
of functional assays combined with the emergence of
single-cell technologies, including single-cell RNA
sequencing48,49,133. New analyses are being reported at
an impressive rate, and the field is in a state of flux.
NaTure RevIeWS | CANcer

Nonetheless, there is a recurrent observation of distinct
CAFs exhibiting either a matrix-producing contractile
phenotype or an immunomodulating secretome —
often termed ‘myoCAFs’ and ‘iCAFs’, with the prefixes
alluding to a myofibroblast phenotype and regulation of
inflammation, respectively. In pancreatic cancer, CAFs
most proximal to the cancer cells exhibit a myoCAF
phenotype, with high TGFβ-driven αSMA expression
and a contractile phenotype33. More distal CAFs exp
ress higher levels of IL-6 and are labelled iCAFs. The
apparent exclusivity of the two phenotypes can be
explained by TGFβ-mediated suppression of the IL-1
receptor, which is responsible for driving NF-κB signalling and subsequent IL-6 expression 20. Breast
cancer also shows divergent CAF phenotypes, with
the primary discriminating marker being FAP. FAP-
high fibroblasts are correlated with Treg cell-mediated
immunosuppression and a poor outcome119, which is
broadly consistent with the tumour rejection observed
following the ablation of FAP+ fibroblasts in experimental systems16. However, FAP+ fibroblasts should
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not be viewed as solely immune modulating, as their
targeting with chimeric antigen receptor (CAR) T cells
leads to reduced matrix deposition134. Another study
reported an NF-κB-driven subset of CAFs expressing GPR77 and CD10, which promote ‘stemness’ and
chemoresistance within breast cancer cells135. In the
long term, it will be important for researchers to coalesce around a consensus for CAF subtypes and nomenclature (discussed in more detail later). Improvements
in multiplexed immunohistochemistry that allow the
analysis of multiple markers simultaneously and more
quantitative methods for determining relative degrees of
marker expression should aid reproducible evaluation
of CAF subtypes.
The issue of CAF heterogeneity raises additional
questions; including whether CAF subtypes might
interconvert or whether they are more stable, possibly
because they are instructed by oncogenic or tumour
suppressor mutations within cancer cells. Knowledge
in this area is currently emerging. Work in PDAC has
shown how KRAS mutation or different p53 mutational
status can influence CAFs 111,136. Mutant p53 drives
TNF production by cancer cells, leading to enhanced
matrix remodelling and perlecan expression by CAFs136.
However, such studies do not preclude additional non-
genetic factors influencing CAF subtype. Indeed, CAFs
isolated from mouse PDAC can be switched from the
αSMA-high and IL-6-producing states through manipu
lation of TGFβ and IL-1 signalling, arguing for considerable plasticity in fibroblast states20. Furthermore,
the responsiveness of matrix production by fibroblasts
and the αSMA promoter to a range of extracellular
cues, including substrate stiffness, supports the idea
that the αSMA-h igh, matrix producing-h igh state

Box 2 | Cancer-associated fibroblast clinical trial activity
Cancer-associated fibroblasts (CAFs) are increasingly viewed as a target that could
be manipulated for therapeutic benefit in patients with cancer. There are now many
clinical trials involving CAF-targeting agents in combination with existing therapies.
The underlying rationale is that by targeting CAFs there will be improvements in the
access of either conventional therapies or T cells to the tumour. In some cases, new
strategies are being developed to target fibroblasts specifically (for example, fibroblast
activation protein (FAP) ligands coupled to cytotoxic drugs165). In other cases, crosstalk
between cancer cells and fibroblasts is targeted (for example, Hedgehog pathway
inhibition166), or existing compounds are found to have a strong influence on CAF
functions and are repurposed as anti-stromal drugs (for example, losartan is primarily
used to treat high blood pressure but also modulates the tumour extracellular
matrix100,101,167,168). Table 1 outlines ongoing clinical trial activity in these areas.

Possible lessons from targeting the Hedgehog pathway in pancreatic cancer
The clinical trial designed to recapitulate the advantageous effect of Hedgehog
pathway inhibition in mouse models of pancreatic ductal adenocarcinoma (PDAC)166
failed to show such benefit and paradoxically reported decreased patient survival in
combination with gemcitabine chemotherapy (NCT01130142)169. The details of this trial
have not yet been described, and subsequent preclinical studies that suppressed in the
long term the CAF subset known to be Hedgehog responsive also demonstrated more
rapid PDAC progression35,36. One possible explanation for this discordance between the
first mouse experiments and the latter ones, and the failed clinical trial, is that CAFs are
interconvertible from Hedgehog responsive to Hedgehog non-responsive over time,
and this should be considered in the design of new studies. Indeed, it is now common
practice for clinical trials to evaluate the numbers of different classes of T cells, and it
would be an important advance if data on CAF numbers and subtypes, at least based
on some key markers, were also captured.
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is reversible63,64,137–139. Once again, irreversible lineage marking approaches in mouse models should be
informative in addressing the interconvertibility of
different CAF subtypes, and improved understanding
of the epigenetic regulation of CAF states should shed
further light on the stability of CAFs.

Targeting CAFs for clinical benefit
Many patient studies have documented how either CAF
number or CAF function is linked to outcome140–142,
and thus being able to target CAFs would represent
an appealing addition to the suite of anticancer therapies. Further targeting mechanisms, such as TGFβ signalling, that activate CAFs or emanate from CAFs to
modulate the tumour phenotype are being intensively
explored143,144. There is already much activity in the area
of CAF targeting — summarized in Box 2, Table 1 and
detailed reviews145,146. However, the breadth of CAF
functions and possible interconvertibility of subtypes
poses a challenge for the field, with preclinical studies
suggesting that the non-specific targeting or deletion of
stromal fibroblasts may not enhance tumour control35,36.
Thus, patient benefit might require targeting of CAF
subtypes or reprogramming of CAFs to either a normal
fibroblast or an antitumorigenic CAF phenotype. This
highlights the importance of defining CAF subtypes and
their inter-relationships. One appealing strategy is to
make CAFs more ‘normal’. An example of this approach
is provided by the targeting of the vitamin D receptor in
pancreatic cancer. Treatment with a vitamin D receptor
ligand caused activated stellate cells to revert to a more
quiescent state and reduced disease aggressiveness23,147
(see Table 1). Therefore, it is important to delineate
whether individual fibroblast populations represent
‘states’ and are therefore interconvertible or whether distinct ‘lineage-restricted’ effects exist as this may dictate a
different therapeutic approach. The functional contribution of CAFs to tumour biology is also typically assumed
to be preserved across tumour types, but this remains to
be demonstrated, and care will be needed when one is
extrapolating between different tumour types.
In practice, achieving clinical benefit may not necessarily require elimination or reprogramming of CAFs,
but could be achieved by blocking signals coming from
the CAFs. For example, targeting CXCL12 signalling
could be considered to be targeting CAFs as they are
the major source of the chemokine in many tumours121.
Similarly, targeting ECM components and downstream signalling represents a means of interfering with
CAF–cancer cell communication. Indeed, many existing
therapies influence CAF–cancer cell communication and
already modulate how CAFs affect cancer cells. As mentioned earlier, BRAF inhibitors can activate stromal
fibroblasts and thereby promote a compensatory mechanism for activating ERK–MAPK in cancer cells78. Many
of the expanding range of receptor tyrosine kinase inhibitors have some activity on FGF and PDGF receptors
that can drive fibroblast function148,149. This is exemplified by the repurposing of nintedanib, which was origi
nally developed with oncology in mind, for treatment
of idiopathic pulmonary fibrosis150. Finally, both conventional DNA damaging chemotherapy and radiotherapy
www.nature.com/nrc
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can trigger changes in CAF biology, with fibrosis being
a common late side effect of radiotherapy151. These data
argue that more studies to assess the extent to which
responses to therapies might be influenced by altered
CAF biology are warranted.

Challenges and recommendations
An emerging framework for nomenclature. A key challenge now facing researchers of CAF biology is nomenclature (Box 3). Ideally a system should be simple enough
to allow it to be used by the wider cancer and stromal
biology communities but not so dogmatic and constrictive that it masks subtle variations in function
and markers. In addition, it must have flexibility to
incorporate fibroblast subtypes that are only currently
being revealed by single-cell transcriptomics and mass
cytometry methods. Although our view was that it is
too soon for definitive nomenclature to be established,
the consensus was that the main determinant of CAF
categorization should be function, informed primarily
by direct experimental evidence and, in some cases,
robust clinical correlation analyses. These categories
should then be linked to markers, ideally cell surface
markers, so that they can be further interrogated in
analyses that might not be compatible with functional
testing. A sensible starting point for such a classification
would be the reiteration that activated fibroblasts can
adopt a high matrix producing and remodelling state
— analogous to the myofibroblast in other pathologies.
This is linked to high levels of TGFβ signalling and
αSMA expression6. It will also be necessary to include
immunomodulation into CAF categories. Although
most studies have suggested an immunosuppressive role
of CAFs121, it should be left open that CAFs could promote immune-mediated tumour surveillance. Indeed,
the function of FRCs in lymph nodes is to make possible
an effective T cell-mediated immune response21. Scope
should also be left for antigen presentation, the meta
bolic state of fibroblasts, and their lineage history to be
incorporated into any nomenclature.
Robust and standardized methods for detecting CAFs
in tissue. Progress in translational studies will require
accurate recording of CAF numbers and subtype within
clinical samples. Clinical studies that target either CAFs
or CAF-associated functions must include measurement
of CAFs in their design. More generally, our consensus
was that CAF metrics should be recorded even in studies that do not have CAFs as their focus, for example
in immuno-oncology trials. This will depend on high-
quality antibodies against CAF marker proteins, which
in many cases are lacking. While reliable αSMA antibodies are available, antibodies against putative CAF
subtype markers often require painstaking optimization,
and this hampers their adoption in clinical pathology
laboratories. The technology around multiplexed mRNA
probes is developing rapidly and, in the long term, this
might provide a better and more flexible solution than
antibody-based methods. Furthermore, researchers are
aware of caveats in studies that involve dissociation of
tumour tissue, for example those using cytometry by
time of flight (CyTOF) and single-cell RNA sequencing.
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Detaching fibroblasts from tissue typically requires more
aggressive methods than for leukocytes, and there is risk
that fibroblasts are substantially under-represented in
studies optimized for leukocyte biology152.
Measuring CAF functions in vitro and in vivo. The diversity of CAF function is reflected in the wide range of
assays used to assess CAF function. While the breadth
of assays is necessary, it presents a challenge when one is
interpreting the literature. In this subsection, we review
the main assays used and highlight key points regarding
interpretation of their results.
The function of CAFs can be directly investigated
in vitro. Given the ability of both serum and stiff substrates to activate fibroblasts, attention should be paid to
the culture conditions used, with lower serum concentrations and matrices with more physiological mechanical
properties being preferable. Furthermore, it is important to consider whether the CAFs being tested are early
passage primary cells or have been in culture for several
passages and even immortalized. Although certain CAF
characteristics are stably maintained in culture, such as
their increased ability to remodel the ECM53, it is highly
likely that some traits are not. Detailed characterization
of how CAF properties change on isolation and longer-
term culture will help to clarify which functional assays
necessitate early passage primary CAFs and which work
equally well after longer periods of cell culture.
Matrix production and remodelling can be easily
measured. CAFs will produce ECM in culture, and this
can be assayed for its composition and quantity using
western blotting, quantitative immunofluorescence and
mass spectrometry methods153. The organization of this
matrix can be determined by immunof luorescence,
frequently staining for fibronectin, and its mechanical properties can be determined by either atomic force
microscopy or shear rheology. Similar techniques can be
applied in vivo, with collagen second-harmonic imaging
frequently used to assess matrix organization. Multi
parametric magnetic resonance imaging (MRI) and
magnetic resonance elastography (MRE) can also be
Box 3 | Key recommendations
• Adoption of a simple, non-constrictive nomenclature
based on cancer-associated fibroblast (CAF) function
• Relate fibroblast markers to function while avoiding
dogmatic schemes that do not account for diversity
of fibroblast states
• Determine the lineage relationship of different
CAF subtypes
• Prioritize identification of strategies that can
reprogramme CAFs rather than ablate them
• Increased reporting of CAF metadata in experimental
studies, including clinical features of the tumour, CAF
marker expression in the original tumour, short tandem
repeat profile, culture conditions and passage number,
and immortalization
• Recording of CAF numbers in clinical studies and
trials, starting with reporting of α-smooth muscle
actin (αSMA) and fibroblast activation protein (FAP)
staining
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used to infer tissue mechanics, with the advantage that
these techniques can be translated to clinical imaging
and used in clinical trials154,155. Histochemical stains to
distinguish collagen, including Masson’s trichrome and
picrosirius red, provide similar information and the use
of crossed polarizing filters during imaging of picrosirius
red-stained sections provides a measure of collagen
crosslinking156. However, most methods for the analysis of pattern lack universal quantitative metrics; in the
future, the implementation of methods from network
topology analysis and the use of spatial statistics will aid
comparison between studies157,158.
The secretome of CAFs is typically measured using
enzyme-linked immunosorbent assay (ELISA) and cyto
kine array tools, with a range of standardized commercial
reagents available. Exosomes can be analysed following
their purification by high-speed centrifugation with
clear guidelines on optimal protocols 159. Crosstalk
with cancer cells is usually evaluated in terms of changes
in growth and invasion. Cells can be directly co-cultured,
with either genetic labels or staining for markers used
to distinguish the cancer cells and fibroblasts, indirectly
co-cultured (that is, separated by a filter) or conditioned
media can be exchanged between separate cultures.
Cell number is the most common growth metric, and
migration either into a 2D ‘wound’ or across a Trans
well are most common invasion metrics. Advances in
3D co-cultures, including the use of organoid cultures
and reconstituted matrices, are allowing in vitro assays
to more closely mimic the in vivo tissue architecture.
In these assays, it should be noted that basement membrane preparations often contain growth factors in
addition to matrix components, leading to the possible
confounding of matrix and growth factor influences on
CAF biology. Pepsinized preparations of collagen I lacking the telopeptide cannot be crosslinked, which leads
to altered dependencies on matrix metalloproteinases
(MMPs) for cancer invasion160. Co-cultures with other
cell types from the tumour microenvironment can
also be informative. For example, fibroblasts can boost
angiogenesis in in vitro assays, with exciting advances in
the development of microfluidic angiogenesis models,
and an increasing number of studies have shown how
they can alter T cell functionality118,161,162.
Two main methods are used to explore CAF functions in vivo: transgenic manipulations and co-injection
methods. The latter are simpler to perform as they
avoid the need for complex mouse crosses. However,
there are some notable caveats. The most challenging
is that as tumours grow they will contain a mixture of
the co-injected CAFs and fibroblasts derived from the
host mouse and, for reasons that are not fully understood, host-derived fibroblasts outgrow co-injected
CAFs. In practice, this favours the early evaluation of
differences between experimental groups and makes
it hard to test longer term phenotypes, such as therapy
responses. Transgenic manipulations using Cre–lox systems to modulate CAFs overcome these issues but have
a different set of issues. The most notable of these is the
choice of the Cre driver line. Currently, no CAF-specific
Cre driver line exists, and even fibroblast-specific Cre
driver lines are complex. Acta2-Cre and Acta2-Cre–ERT
182 | March 2020 | volume 20

can be used, but they will also drive recombination in
smooth muscle cells and myoepithelial cells, which
poses a particular challenge in mouse models of breast
cancer, which has a high frequency of these cell types in
the tumour microenvironment. Fsp1-Cre has the caveat
that fibroblast-specific protein 1 (FSP1; also known
as S100A4) is expressed by subsets of myeloid cells.
Pdgfra-Cre and Col1a2-Cre are more generic fibroblast
drivers, but the former gene is expressed in some neurons and the latter is expressed in osteoblasts. These
issues highlight the importance of using ‘Cre-reporter
mice’ to check that recombination is being driven in
the intended subset of cells and not more permissively.
Following its expression, Cre recombinase can then be
used to specifically knock out suitably ‘floxed’ genes in
fibroblasts or inhibit or ablate fibroblasts by driving the
expression of viral thymidine kinase or diphtheria toxin
receptor, respectively.
The other major challenge with in vivo models is how
to drive tumorigenesis if the Cre–lox system is used to
manipulate CAFs. Injection of tumour cells can be used,
but this is not always ideal as it bypasses the early stages
of tumour initiation. Chemical carcinogenesis is another
option, but it is not always easy to control tumour burden, and the cancer genotypes will be variable. Finally,
combining Cre–lox and Flp–FRT (flippase recognition
target) recombination systems offers an elegant way to
manipulate both tumour and fibroblasts163. Once the
tumour is established, various metrics relating to CAF
function can be measured, including matrix organization
and crosslinking, tissue mechanics, tumour vascular
ization, tumour growth, metastatic spread, immune
infiltrate and therapy response. However, this approach
is very resource and time intensive, and this poses a
barrier for many researchers.
An awareness of the caveats of the assays described
above and subsequent improvements to the methods will
aid further progress. The use of CAFs that have been
established in culture allows molecular perturbations,
such as CRISPR gene editing, and the easy repetition
of experiments. In the future it will be desirable to
determine primary culture conditions that most accurately preserve the in vivo phenotype of CAFs; this is
likely to involve considering both the medium and the
substrate, with several studies showing how culture in
3D conditions can return fibroblasts to their original
phenotype within tissue10,142. Combining this with ongoing improvements in the ability to manipulate primary
cells will allow assays with human cells that more closely
mimic the tumour context. For analysis of interplay with
T cells, it will be desirable to isolate cancer cells, CAFs
and tumour-infiltrating lymphocytes from the same
patient. Improvements in tumour tissue slice culture
methods should also be considered for the analysis of
CAF biology.
Reporting CAF metadata. As with all experimental science, the issue of reproducibility is crucial. Research
into CAFs is greatly made possible by their ability to be
cultured in vitro, but the process of cell culture and the
exact conditions can influence cell behaviours. Increased
reporting of CAF metadata will improve standardization
www.nature.com/nrc
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and robustness in the field. We recommend that studies
involving CAFs document the following:
• An absence of the mutations that drive the tumour
from which they originate. CAFs may accrue mutations, but it is necessary to exclude that they are simply
cancer cells that have undergone EMT. Cancer cells
that have undergone a profound EMT clearly warrant
detailed study and comparison with CAFs, but these
cells should be considered distinct from CAFs.
• The spatial position within the tumour from which
the biopsy was taken — central versus margin. If
‘normal’ fibroblasts are isolated at the same time from
non-cancerous tissue, then the distance of this tissue
from the margin should be recorded.
• Key clinical (stage, grade, prior treatment regimen
and driver mutations (if known)) and histological
features of the tumour from which the CAFs originate, including ideally staining for CAF markers and
the age of the patient or mouse.
• Short tandem repeat profiles of cultured CAFs to
allow unambiguous identification of CAFs in subsequent studies. This will mitigate against inadvertent
cross-contamination of cultures.
• The passage number of cultured CAFs and the
immortalization method used, if any. Details of
the culture medium should also be recorded; in parti
cular, serum percentage, addition of exogenous TGFβ,
culture substrate or matrix (including type of Matrigel
and whether collagen I is telopeptide intact).

Conclusions
Research into CAFs is at an exciting and critical stage.
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